search
Back to results

Muscle Abnormalities in Children With XLH (MDmuscleXLH)

Primary Purpose

Muscle Weakness, XLH

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
MRI
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Muscle Weakness focused on measuring XLH rickets, IMAT, intraMAT, muscle weakness, MRI

Eligibility Criteria

5 Years - 17 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria common criteria to the 2 groups:

  • Age: between 5 and 17 years.
  • Sex: male or female.
  • Informed consent, signed by both parents or holder of parental autority after being informated of the study.
  • Affiliation to a social security schema or having the right to.

Inclusion criteria for XLH Patients :

  • Patient suffer of X-linked hypophosphatemia rickets.
  • Severity of clinical and radiological damage (pain, muscle weakness and severe bone deformities).
  • Growth in progress (bone age less than 15 years).
  • Child under conventional treatment: patient responding to conventional treatment or
  • under treatment with Burosumab (patient in treatment failure under treatment conventional).

incluion criteria for helthy volunteers :

  • Healthy voluntary subjects, not suffering from XLH.
  • Matching by age (+/- 6 months) and sex.

Exclusion Criteria common to the 2 groups :

  • Not being able to stay still during the MRI examination (approximately 45 min).
  • Growth completed.
  • History of lower limb surgery.
  • Contraindications to MRI
  • Holders of parental authority under AME.
  • Holders of parental authority under tutorship / curatorship.

Exclusion criteria for Healthy volunteers :

  • Patients with endocrine, contracted or muscular pathology.
  • Patient receives a long-term treatment.
  • Patients with a high athletic level.
  • BMI-IOTF <20 or> 27.8

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Other

    Other

    Arm Label

    patients with X-linked hypophosphatemic

    healthy volunteers

    Arm Description

    Patient group composed of 10 patients aged between 5 to 17 years old, female or male, with X-linked hypophosphatemic (XLH) rickets, severity of clinical and radiological damage (pain, muscle weakness and severe bone deformities) and ongoing growth (lesser bone age than 15 years old), child under conventional treatment

    control group composed of 20 helthy volunteers aged between 5 to 17 years old, female or male, without any endocrine pathology, not suffering from XLH, matching by age (+/- 6 months) and sex

    Outcomes

    Primary Outcome Measures

    Quantify and compare muscle composition in XLH children versus healthy control children to demonstrate a link between muscle function and muscle quality.
    calculation of inter-muscular adipose tissue will be done in cm2

    Secondary Outcome Measures

    Measurement of muscle strength on force platforms, during gait analysis. Power test by mechanography of the jump (bipod and monopodal). Grasping test and correlation of fatty infiltration and functional data.
    The Outcome Measure is BMI (Kg/m²)
    Quantitative analysis of the muscles of the lower limbs (volume and length)
    The Outcome Measure is BMI (Kg/m²)

    Full Information

    First Posted
    January 24, 2022
    Last Updated
    March 28, 2022
    Sponsor
    Assistance Publique - Hôpitaux de Paris
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05312086
    Brief Title
    Muscle Abnormalities in Children With XLH
    Acronym
    MDmuscleXLH
    Official Title
    Prospective Analysis of Quantitative and Qualitative Muscle Abnormalities in Children With X-linked Hypophosphatemia (XLH)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    April 15, 2022 (Anticipated)
    Primary Completion Date
    June 15, 2023 (Anticipated)
    Study Completion Date
    June 15, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Assistance Publique - Hôpitaux de Paris

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    XLH rickets is a rare disease with muscle weakness. Fat parameters such as IMAT and intraMAT could be increased in this disease. IMAT and intraMAT will be calculated on MRI for 11 XLH children versus 20 typically developing children. The investigator will compare the percentage of IMAT in the XLH group versus control group and the difference concerning the intraMAT between the two groups.
    Detailed Description
    Single-center, prospective, non-randomized, controlled study with XLH and healthy volunteer children. This study involves performing muscle MRI in healthy child volunteers to assess and compare the structure and composition of muscles to those of muscles in children with XLH pathology (muscle MRI of XLH patients is performed as part of standard medical care). During this study we will have two groups: XLH group and a control group with typically developing children. In the XLH group, composed of 10 patients aged between 5 ans 17 years, female or male and ongoing growth (lesser bone age than 15 years old), have XLH and the most severe radiological deformities,clinical complications (pain and muscular weakness), have already done a muscle MRI of the lower limb during their follow-up. The control group composed of 20 healthy volunteers aged between 5 ans 17 years old, female or male and without any endocrine pathology. A muscle MRI is necessary for healthy volunteers. Every child will be alone After signing the informed consent by the 2 parents, the patient or the healthy volunteer and his parents, the MRI assessment will be performed on the same day. Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, i.e. approximately 45 minutes. Performing MRI does not require the injection of contrast products or radiopharmaceuticals.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Muscle Weakness, XLH
    Keywords
    XLH rickets, IMAT, intraMAT, muscle weakness, MRI

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    30 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    patients with X-linked hypophosphatemic
    Arm Type
    Other
    Arm Description
    Patient group composed of 10 patients aged between 5 to 17 years old, female or male, with X-linked hypophosphatemic (XLH) rickets, severity of clinical and radiological damage (pain, muscle weakness and severe bone deformities) and ongoing growth (lesser bone age than 15 years old), child under conventional treatment
    Arm Title
    healthy volunteers
    Arm Type
    Other
    Arm Description
    control group composed of 20 helthy volunteers aged between 5 to 17 years old, female or male, without any endocrine pathology, not suffering from XLH, matching by age (+/- 6 months) and sex
    Intervention Type
    Other
    Intervention Name(s)
    MRI
    Intervention Description
    Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, about 45 minutes. Performing MRI does not require the injection of contrast products or radiopharmaceuticals.
    Primary Outcome Measure Information:
    Title
    Quantify and compare muscle composition in XLH children versus healthy control children to demonstrate a link between muscle function and muscle quality.
    Description
    calculation of inter-muscular adipose tissue will be done in cm2
    Time Frame
    1 day
    Secondary Outcome Measure Information:
    Title
    Measurement of muscle strength on force platforms, during gait analysis. Power test by mechanography of the jump (bipod and monopodal). Grasping test and correlation of fatty infiltration and functional data.
    Description
    The Outcome Measure is BMI (Kg/m²)
    Time Frame
    1 day
    Title
    Quantitative analysis of the muscles of the lower limbs (volume and length)
    Description
    The Outcome Measure is BMI (Kg/m²)
    Time Frame
    1 day

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    5 Years
    Maximum Age & Unit of Time
    17 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria common criteria to the 2 groups: Age: between 5 and 17 years. Sex: male or female. Informed consent, signed by both parents or holder of parental autority after being informated of the study. Affiliation to a social security schema or having the right to. Inclusion criteria for XLH Patients : Patient suffer of X-linked hypophosphatemia rickets. Severity of clinical and radiological damage (pain, muscle weakness and severe bone deformities). Growth in progress (bone age less than 15 years). Child under conventional treatment: patient responding to conventional treatment or under treatment with Burosumab (patient in treatment failure under treatment conventional). incluion criteria for helthy volunteers : Healthy voluntary subjects, not suffering from XLH. Matching by age (+/- 6 months) and sex. Exclusion Criteria common to the 2 groups : Not being able to stay still during the MRI examination (approximately 45 min). Growth completed. History of lower limb surgery. Contraindications to MRI Holders of parental authority under AME. Holders of parental authority under tutorship / curatorship. Exclusion criteria for Healthy volunteers : Patients with endocrine, contracted or muscular pathology. Patient receives a long-term treatment. Patients with a high athletic level. BMI-IOTF <20 or> 27.8
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Agnés LINGLART, Pr
    Phone
    0145217116
    Email
    agnes.linglart@aphp.fr
    First Name & Middle Initial & Last Name or Official Title & Degree
    Philippe WICART, Pr
    Phone
    0144494310
    Email
    p.wicart@aphp.fr

    12. IPD Sharing Statement

    Learn more about this trial

    Muscle Abnormalities in Children With XLH

    We'll reach out to this number within 24 hrs